Who
James E. Levine
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Kazia Therapeutics; Chief Financial Officer, Cardiff Oncology; Chief Financial Officer, Cidara Therapeutics; President & CEO, Verenium.
In numbers
- Trades disclosed
- 55
- Buys
- 13
- Sells
- 0
- Bought
- $758K
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 0
- First trade
- 6 May 2009
- Last trade
- 19 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Jun 2026filed 23 Jun 2026 | KZIA Kazia Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 19 Jun 2026filed 23 Jun 2026 | KZIA Kazia Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 11 Mar 2025filed 13 Mar 2025 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —332,621 at $0.00 | filing |
| 18 Dec 2024filed 18 Dec 2024 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $12K2,400 at $5.00 | filing |
| 17 Dec 2024filed 18 Dec 2024 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $15K2,752 at $5.42 | filing |
| 16 Dec 2024filed 18 Dec 2024 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $9,8202,564 at $3.83 | filing |
| 7 Mar 2024filed 7 Mar 2024 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —205,008 at $0.00 | filing |
| 15 Mar 2023filed 16 Mar 2023 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —197,472 at $0.00 | filing |
| 16 Sep 2022filed 19 Sep 2022 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $47K30,000 at $1.56 | filing |
| 9 Mar 2022filed 10 Mar 2022 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —170,016 at $0.00 | filing |
| 10 Sep 2021filed 13 Sep 2021 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $33K5,000 at $6.62 | filing |
| 10 Sep 2021filed 13 Sep 2021 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $34K5,000 at $6.75 | filing |
| 10 Sep 2021filed 13 Sep 2021 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $64K10,000 at $6.38 | filing |
| 10 Sep 2021filed 13 Sep 2021 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $32K5,000 at $6.35 | filing |
| 10 Sep 2021filed 13 Sep 2021 | CRDF Cardiff OncologyBiotechnology | SEC FORM 4 Bought | $32K5,000 at $6.32 | filing |
| 12 Jul 2021filed 12 Jul 2021 | CRDF Cardiff Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —390,000 at $0.00 | filing |
| 17 Mar 2021filed 19 Mar 2021 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code A | —130,000 at $0.00 | filing |
| 10 Nov 2020filed 12 Nov 2020 | Cidara Therapeutics | SEC FORM 4 Bought | $101K50,000 at $2.01 | filing |
| 19 Mar 2020filed 23 Mar 2020 | Cidara Therapeuticsoption or derivative | SEC FORM 4 Code M | —110,000 at $0.00 | filing |
| 19 Mar 2020filed 23 Mar 2020 | Cidara Therapeutics | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.